CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results

CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of
                     the "Flint" CRP Human Study Results

PR Newswire

GLEN ALLEN, Va., Oct. 26, 2012

GLEN ALLEN, Va., Oct. 26, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ:
STSI) announced today that the press release issued 10/24/2012, titled "Star
Scientific Announces Successful First Look at the "Flint" CRP Human Study and
Provides Updated Report on ASAP Human Thyroid Study", incorrectly stated the
interim results of the "Flint" CRP study. In the release, the Company
reported: "After one month of supplementation, CRP levels dropped in 26% of
the subjects with diabetes, compared with a drop in CRP levels in 12% of the
general trial population of subjects who did not have diabetes." These figures
reflected an understatement of the decrease in CRP levels after anatabine
supplementation. The correct figures are as follows: 11 of 18 (61%) diabetic
subjects on metformin had a CRP reduction, as did 31 of 81 (38%) subjects in
the general trial population not taking metformin. Overall, 42 of 99 (42%)
subjects had a decrease in CRP after only one month with anatabine

The anatabine used in the clinical trial is made under the Company's patented
process and is the main ingredient in its Anatabloc® product, which is sold in
GNC stores nationwide.

(Logo: )

Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to statements identified
by words such as "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's
management and are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but
not limited to, results of clinical trials, the challenges inherent in new
product development initiatives, including the continued development and
market acceptance of our nutraceutical and low-TSNA tobacco products, our
ability to license and protect our intellectual property, our ability to raise
additional capital in the future that is necessary to maintain our business,
changes in government policy and/or regulation, including with respect to our
nutraceutical and low-TSNA tobacco products, as well as other risks discussed
from time to time in our filings with the Securities and Exchange Commission,
including, without limitation, our annual report on Form 10-K for the fiscal
year ended December 31, 2011. We undertake no duty to update any
forward-looking statement or any information contained in this press release
or in other public disclosures at any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to
promote maintenance of a healthy metabolism, as well as to reduce the harm
associated with the use of tobacco at every level. Over the last several
years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star
Scientific has been engaged in the manufacturing, sale, and marketing of two
nutraceutical dietary supplements, and the development of other nutraceuticals
and pharmaceuticals. The company also has continued to pursue the development,
implementation, and licensing of the technology behind its proprietary
StarCured® tobacco curing process, which substantially prevents the formation
of carcinogenic toxins present in tobacco and tobacco smoke, primarily the
tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable
tobacco products. Rock Creek Pharmaceuticals has scientific and research
offices in Gloucester, MA, and a regulatory office in Washington, DC. Star
Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive,
Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC;
and a manufacturing facility in Chase City, VA.

Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.

SOURCE Star Scientific, Inc.

Press spacebar to pause and continue. Press esc to stop.